Loading…
CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury
The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue fr...
Saved in:
Published in: | The Journal of pathology 2018-10, Vol.246 (2), p.191-204 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93 |
---|---|
cites | cdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93 |
container_end_page | 204 |
container_issue | 2 |
container_start_page | 191 |
container_title | The Journal of pathology |
container_volume | 246 |
creator | González‐Guerrero, Cristian Morgado‐Pascual, José Luis Cannata‐Ortiz, Pablo Ramos‐Barron, María Angeles Gómez‐Alamillo, Carlos Arias, Manuel Mezzano, Sergio Egido, Jesús Ruiz‐Ortega, Marta Ortiz, Alberto Ramos, Adrián M |
description | The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/path.5132 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2110260205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2110260205</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</originalsourceid><addsrcrecordid>eNp1kL9OwzAQhy0EoqUw8AIoEhNDytnOP49VBRSpEgxlRJFjX9S0aRLsBMjGI_CMPAkuLWwsdzrdd99JP0LOKYwpALtuZLsch5SzAzKkICJfJCI6JEO3Yz4PaDwgJ9auAECIMDwmAyZEEgTAh-R5Op0z8LKyVmup0SsqZVBatF67RM_iK5qi7b069ypslqZu6_dCeXlduipVob8-PotKdwq1G7sWvXWhK-ydZ9WZ_pQc5bK0eLbvI_J0e7OYzvz5w939dDL3FQ858zUPYwFhBBEVTPCMBpRmkORa5JjECkWmZBhlcRYBo0xGWsecywCoShiHTPARudx5G1O_dGjbdFV3pnIvU0YpMHcHoaOudpQytbUG87QxxUaaPqWQboNMt0Gm2yAde7E3dtkG9R_5m5wDrnfAW1Fi_78pfZwsZj_Kb3xLfTo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2110260205</pqid></control><display><type>article</type><title>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>González‐Guerrero, Cristian ; Morgado‐Pascual, José Luis ; Cannata‐Ortiz, Pablo ; Ramos‐Barron, María Angeles ; Gómez‐Alamillo, Carlos ; Arias, Manuel ; Mezzano, Sergio ; Egido, Jesús ; Ruiz‐Ortega, Marta ; Ortiz, Alberto ; Ramos, Adrián M</creator><creatorcontrib>González‐Guerrero, Cristian ; Morgado‐Pascual, José Luis ; Cannata‐Ortiz, Pablo ; Ramos‐Barron, María Angeles ; Gómez‐Alamillo, Carlos ; Arias, Manuel ; Mezzano, Sergio ; Egido, Jesús ; Ruiz‐Ortega, Marta ; Ortiz, Alberto ; Ramos, Adrián M</creatorcontrib><description>The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.5132</identifier><identifier>PMID: 29984403</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Acids ; acute kidney injury ; Animal models ; calcification ; Calcinosis ; CCL20 ; CCL20 protein ; CCR6 ; CCR6 protein ; chemokine ; Chemokines ; Cisplatin ; Fibrosis ; Folic acid ; Inflammation ; Inflammatory response ; Interstitial cells ; Kidney diseases ; Kidneys ; Leukocytes (neutrophilic) ; Mice ; Overdose ; Rarefaction ; Renal failure ; Treg ; Vitamin B</subject><ispartof>The Journal of pathology, 2018-10, Vol.246 (2), p.191-204</ispartof><rights>Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>Copyright © 2018 Pathological Society of Great Britain and Ireland</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</citedby><cites>FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</cites><orcidid>0000-0003-2718-3591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29984403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González‐Guerrero, Cristian</creatorcontrib><creatorcontrib>Morgado‐Pascual, José Luis</creatorcontrib><creatorcontrib>Cannata‐Ortiz, Pablo</creatorcontrib><creatorcontrib>Ramos‐Barron, María Angeles</creatorcontrib><creatorcontrib>Gómez‐Alamillo, Carlos</creatorcontrib><creatorcontrib>Arias, Manuel</creatorcontrib><creatorcontrib>Mezzano, Sergio</creatorcontrib><creatorcontrib>Egido, Jesús</creatorcontrib><creatorcontrib>Ruiz‐Ortega, Marta</creatorcontrib><creatorcontrib>Ortiz, Alberto</creatorcontrib><creatorcontrib>Ramos, Adrián M</creatorcontrib><title>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</title><title>The Journal of pathology</title><addtitle>J Pathol</addtitle><description>The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><subject>Acids</subject><subject>acute kidney injury</subject><subject>Animal models</subject><subject>calcification</subject><subject>Calcinosis</subject><subject>CCL20</subject><subject>CCL20 protein</subject><subject>CCR6</subject><subject>CCR6 protein</subject><subject>chemokine</subject><subject>Chemokines</subject><subject>Cisplatin</subject><subject>Fibrosis</subject><subject>Folic acid</subject><subject>Inflammation</subject><subject>Inflammatory response</subject><subject>Interstitial cells</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Leukocytes (neutrophilic)</subject><subject>Mice</subject><subject>Overdose</subject><subject>Rarefaction</subject><subject>Renal failure</subject><subject>Treg</subject><subject>Vitamin B</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kL9OwzAQhy0EoqUw8AIoEhNDytnOP49VBRSpEgxlRJFjX9S0aRLsBMjGI_CMPAkuLWwsdzrdd99JP0LOKYwpALtuZLsch5SzAzKkICJfJCI6JEO3Yz4PaDwgJ9auAECIMDwmAyZEEgTAh-R5Op0z8LKyVmup0SsqZVBatF67RM_iK5qi7b069ypslqZu6_dCeXlduipVob8-PotKdwq1G7sWvXWhK-ydZ9WZ_pQc5bK0eLbvI_J0e7OYzvz5w939dDL3FQ858zUPYwFhBBEVTPCMBpRmkORa5JjECkWmZBhlcRYBo0xGWsecywCoShiHTPARudx5G1O_dGjbdFV3pnIvU0YpMHcHoaOudpQytbUG87QxxUaaPqWQboNMt0Gm2yAde7E3dtkG9R_5m5wDrnfAW1Fi_78pfZwsZj_Kb3xLfTo</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>González‐Guerrero, Cristian</creator><creator>Morgado‐Pascual, José Luis</creator><creator>Cannata‐Ortiz, Pablo</creator><creator>Ramos‐Barron, María Angeles</creator><creator>Gómez‐Alamillo, Carlos</creator><creator>Arias, Manuel</creator><creator>Mezzano, Sergio</creator><creator>Egido, Jesús</creator><creator>Ruiz‐Ortega, Marta</creator><creator>Ortiz, Alberto</creator><creator>Ramos, Adrián M</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0003-2718-3591</orcidid></search><sort><creationdate>201810</creationdate><title>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</title><author>González‐Guerrero, Cristian ; Morgado‐Pascual, José Luis ; Cannata‐Ortiz, Pablo ; Ramos‐Barron, María Angeles ; Gómez‐Alamillo, Carlos ; Arias, Manuel ; Mezzano, Sergio ; Egido, Jesús ; Ruiz‐Ortega, Marta ; Ortiz, Alberto ; Ramos, Adrián M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acids</topic><topic>acute kidney injury</topic><topic>Animal models</topic><topic>calcification</topic><topic>Calcinosis</topic><topic>CCL20</topic><topic>CCL20 protein</topic><topic>CCR6</topic><topic>CCR6 protein</topic><topic>chemokine</topic><topic>Chemokines</topic><topic>Cisplatin</topic><topic>Fibrosis</topic><topic>Folic acid</topic><topic>Inflammation</topic><topic>Inflammatory response</topic><topic>Interstitial cells</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Leukocytes (neutrophilic)</topic><topic>Mice</topic><topic>Overdose</topic><topic>Rarefaction</topic><topic>Renal failure</topic><topic>Treg</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González‐Guerrero, Cristian</creatorcontrib><creatorcontrib>Morgado‐Pascual, José Luis</creatorcontrib><creatorcontrib>Cannata‐Ortiz, Pablo</creatorcontrib><creatorcontrib>Ramos‐Barron, María Angeles</creatorcontrib><creatorcontrib>Gómez‐Alamillo, Carlos</creatorcontrib><creatorcontrib>Arias, Manuel</creatorcontrib><creatorcontrib>Mezzano, Sergio</creatorcontrib><creatorcontrib>Egido, Jesús</creatorcontrib><creatorcontrib>Ruiz‐Ortega, Marta</creatorcontrib><creatorcontrib>Ortiz, Alberto</creatorcontrib><creatorcontrib>Ramos, Adrián M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González‐Guerrero, Cristian</au><au>Morgado‐Pascual, José Luis</au><au>Cannata‐Ortiz, Pablo</au><au>Ramos‐Barron, María Angeles</au><au>Gómez‐Alamillo, Carlos</au><au>Arias, Manuel</au><au>Mezzano, Sergio</au><au>Egido, Jesús</au><au>Ruiz‐Ortega, Marta</au><au>Ortiz, Alberto</au><au>Ramos, Adrián M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J Pathol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>246</volume><issue>2</issue><spage>191</spage><epage>204</epage><pages>191-204</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><abstract>The chemokine CCL20 activates the CCR6 receptor and has been implicated in the pathogenesis of glomerular injury. However, it is unknown whether it contributes to acute kidney injury (AKI). We identified CCL20 as upregulated in a systems biology strategy combining transcriptomics of kidney tissue from experimental toxic folic acid‐induced AKI and from stressed cultured tubular cells and have explored the expression and function of CCL20 in experimental and clinical AKI. CCL20 upregulation was confirmed in three models of kidney injury induced by a folic acid overdose, cisplatin or unilateral ureteral obstruction. In injured kidneys, CCL20 was expressed by tubular, endothelial, and interstitial cells, and was also upregulated in human kidneys with AKI. Urinary CCL20 was increased in human AKI and was associated with severity. The function of CCL20 in nephrotoxic folic acid‐induced AKI was assessed by using neutralising anti‐CCL20 antibodies or CCR6‐deficient mice. CCL20/CCR6 targeting increased the severity of kidney failure and mortality. This was associated with more severe histological injury, nephrocalcinosis, capillary rarefaction, and fibrosis, as well as higher expression of tubular injury‐associated genes. Surprisingly, mice with CCL20 blockade had a lower tubular proliferative response and a higher number of cells in the G2/M phase, suggesting impaired repair mechanisms. This may be related to a lower influx of Tregs, despite a milder inflammatory response in terms of chemokine expression and infiltration by IL‐17+ cells and neutrophils. In conclusion, CCL20 has a nephroprotective role during AKI, both by decreasing tissue injury and by facilitating repair. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>29984403</pmid><doi>10.1002/path.5132</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-2718-3591</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3417 |
ispartof | The Journal of pathology, 2018-10, Vol.246 (2), p.191-204 |
issn | 0022-3417 1096-9896 |
language | eng |
recordid | cdi_proquest_journals_2110260205 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Acids acute kidney injury Animal models calcification Calcinosis CCL20 CCL20 protein CCR6 CCR6 protein chemokine Chemokines Cisplatin Fibrosis Folic acid Inflammation Inflammatory response Interstitial cells Kidney diseases Kidneys Leukocytes (neutrophilic) Mice Overdose Rarefaction Renal failure Treg Vitamin B |
title | CCL20 blockade increases the severity of nephrotoxic folic acid‐induced acute kidney injury |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T23%3A42%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CCL20%20blockade%20increases%20the%20severity%20of%20nephrotoxic%20folic%20acid%E2%80%90induced%20acute%20kidney%20injury&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Gonz%C3%A1lez%E2%80%90Guerrero,%20Cristian&rft.date=2018-10&rft.volume=246&rft.issue=2&rft.spage=191&rft.epage=204&rft.pages=191-204&rft.issn=0022-3417&rft.eissn=1096-9896&rft_id=info:doi/10.1002/path.5132&rft_dat=%3Cproquest_cross%3E2110260205%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-d35790560619293b1411b08fd9fe87ce9bca56b7b60212a6dd733a401c8230b93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2110260205&rft_id=info:pmid/29984403&rfr_iscdi=true |